NUMAFERM GmbH
NUMAFERM closes licensing agreement with PEPDesign
DGAP-News: NUMAFERM GmbH / Key word(s): Alliance NUMAFERM closes licensing agreement with PEPDesign – Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform – Industry seeks optimized generic drug manufacturing methods after liraglutide patent expiration Düsseldorf (Germany) and Pūrē (Latvia), 22. July 2019: The Düsseldorf-based NUMAFERM GmbH has signed a licensing agreement for its unique manufacturing process for peptides with PEPDesign SIA. NUMAFERM’s technology platform will be applied to the production of diabetes and obesity drugs. Under the terms of the agreement, PEPDesign will continue to drive production of the diabetes drug liraglutide in the direction of Good Manufacturing Practice (GMP) for production and market launch. Compared to current peptide production processes, the NUMAFERM biotechnological manufacturing process is cost-effective and yields a superior product purity. The shared objective of the collaboration is to identify a suitable partner for commercialization of the manufactured drug. Sales of liraglutide currently amount to eight billion USD, making it one of the highest-selling diabetes drugs worldwide. Liraglutide’s patent protection will expire in August 2022. Financial details of the collaboration were not disclosed. “This contract confirms that our award-winning technology meets a market demand and offers the industry and attractive production strategy,” said Philipp Bürling, Co-Founder and Chief Financial Officer (CFO) of NUMAFERM. “With the help of our technology, peptides can be produced efficiently, inexpensively and with a higher product purity. In the context of the license agreement we strengthen our cooperation with PEPDesign and enter into the pre-commercialization phase.” Dr. Christian Ewers, Co-Founder and Chief Executive Officer (CEO) of PEPDesign went on to say: “Liraglutide is an extremely exciting development project with tremendous market potential, as sales are projected to reach 20 billion USD by 2022. Based on this, a low cost production process is of inestimable value. The quality observed in the first samples provided by NUMAFERM was exceptional. I am thrilled to inlicence this groundbreaking technology.” Dr. Christian Schwarz, NUMAFERM Co-Founder and Chief Executive Officer (CEO), commented: “This agreement reflects the amazing work of our team and the increasing reputation of NUMAFERM in the market. Additional projects are ongoing with well-known industry partners, and we are optimistic to be involved in launches of exciting products in the near future.” In addition to diabetes and obesity, peptides play a major role in pharmaceutical pipelines. More than 500 peptide drugs are currently under development.”Our clients’ peptide projects that were previously non-economical are being rolled-out again. This holds true for the pharma industry as well as for non-pharma applications where peptide-based innovations are under development in sectors such as veterinary, cosmetic, agriculture, aquaculture and nutrition” said Schwarz. ### Notes to Editors: About peptides and their production with NUMAFERM technology About NUMAFERM GmbH About PEPDesign SIA For more information, please contact: MC Services AG
22.07.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |